Status:
COMPLETED
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Colorectal Cancer
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this research is to determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactine...
Eligibility Criteria
Inclusion
- Patients with colorectal cancer, lung cancer, breast cancer, and glioblastoma patients that have been treated with Bevacizumab for at least 1 month
- Adults (18 years of age or older)
Exclusion
- Patients who are taking medications known to affect serum prolactin levels
- Patients who are pregnant
- Patients who have pituitary disease
- Minors (Under the age of 18)
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00973557
Start Date
September 1 2009
End Date
January 1 2012
Last Update
February 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048